| 62.45 -0.31 (-0.49%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 77.36 | 1-year : | 90.36 |
| Resists | First : | 66.23 | Second : | 77.36 |
| Pivot price | 57.1 |
|||
| Supports | First : | 58.05 | Second : | 53 |
| MAs | MA(5) : | 58.41 |
MA(20) : | 56.92 |
| MA(100) : | 45.64 |
MA(250) : | 35.64 |
|
| MACD | MACD : | 1.3 |
Signal : | 1 |
| %K %D | K(14,3) : | 62.7 |
D(3) : | 49.5 |
| RSI | RSI(14): 67.9  |
|||
| 52-week | High : | 66.23 | Low : | 16.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TVTX ] has closed Bollinger Bands are 10.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 65.52 - 65.9 | 65.9 - 66.24 |
| Low: | 61.28 - 61.68 | 61.68 - 62.04 |
| Close: | 61.88 - 62.52 | 62.52 - 63.09 |
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Thu, 06 Aug 2026
FMR LLC (TVTX) discloses 7.1M Travere Therapeutics shares under amended 13G - Stock Titan
Thu, 06 Aug 2026
Travere Therapeutics Q2 Earnings: Why I'm Downgrading To Hold (Again) (NASDAQ:TVTX) - Seeking Alpha
Wed, 05 Aug 2026
Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $68.36, Implies 22% Upside - TradingView
Wed, 05 Aug 2026
Travere Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
Wed, 05 Aug 2026
S&P 500 Futures Up in Premarket Trading; Shopify, Travere Therapeutics Lead - Barron's
Wed, 05 Aug 2026
Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 114 (%) |
| Shares Short | 12,020 (K) |
| Shares Short P.Month | 13,440 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.07 |
| Profit Margin | -4 % |
| Operating Margin | -29.1 % |
| Return on Assets (ttm) | -6.5 % |
| Return on Equity (ttm) | -69.4 % |
| Qtrly Rev. Growth | 55.5 % |
| Gross Profit (p.s.) | 3.22 |
| Sales Per Share | 5.76 |
| EBITDA (p.s.) | 0.17 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 40 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -124.91 |
| PEG Ratio | 0 |
| Price to Book value | 58.36 |
| Price to Sales | 10.83 |
| Price to Cash Flow | 146.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|